Symbiomix To Present Data On Solosec (Secnidazole) Oral Granules At 2016 AAPS Annual Meeting And Exposition
11/7/2016 10:45:13 AM
Newark, NJ, November 7, 2016 – Symbiomix, a biopharmaceutical company bringing innovative medicines to market for prevalent gynecological infections, today announced that data from studies of Solosec™ (secnidazole, also known as SYM-1219) oral granules will be presented at the 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition taking place November 13-17, 2016 at the Colorado Convention Center in Denver, Colorado. Solosec™ is a potent, next-generation, investigational 5-nitroimidazole antibiotic with enhanced pharmacokinetic properties, and is anticipated to be the first and only single-dose oral therapy approved for bacterial vaginosis (BV).
Details for the poster presentations are as follows:
? Poster 19M0230: “A Phase 1, Open-Label, Single-Dose, Randomized, 3-Way Crossover Study to Assess the Pharmacokinetics and Safety of SYM-1219 Containing 2 g of Secnidazole Administered Orally as Granules in Pudding, Yogurt, or Applesauce in Healthy Female Volunteers” is scheduled to be presented at 2:30 p.m. MT on Monday, November 14, 2016.
? Poster 04W1230: “SYM-1219: Oral Single-Dose Safety Pharmacology Studies to Determine Possible Secnidazole Toxicity," is scheduled to be presented at 12:30 p.m. MT on Wednesday, November 16, 2016.
Symbiomix recently announced that it is accelerating plans for the commercial launch of Solosec™, and the company is working towards a near-term submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). Solosec™ has been designated a Qualified Infectious Disease Product (QIDP) by the FDA for the treatment of BV and received Fast Track designation from the agency in 2015, making Solosec™ eligible for Priority Review and at least 10 years of market exclusivity.
Solosec™ is a potent, next-generation, investigational 5-nitroimidazole antibiotic with enhanced pharmacokinetic properties. Solosec™ is anticipated to be the first and only single-dose oral therapy approved for BV, which may lead to better adherence to therapy and therefore better patient outcomes. In clinical trials Solosec™ demonstrated efficacy for the treatment of BV with only a single, oral, two-gram dose, thereby additionally providing excellent safety, tolerability and adherence.
BV is the most prevalent gynecological infection in the U.S. among women ages 15 to 44 [1,2]. Today
more than four million women are treated in the US for BV annually . More than 50 percent of
women treated for BV have a recurrence within 12 months .
The U.S. Centers for Disease Control and Prevention (CDC) has stated that BV can cause serious health
? Increasing the risk of HIV transmission;
? Increasing the risk of contracting other sexually transmitted diseases, such as chlamydia and
gonorrhea, which, if untreated, may lead to pelvic inflammatory disease and infertility; and,
? In pregnant women, increasing the risk of delivering a baby too early .
BV disproportionately affects disadvantaged populations, including women of color, and may contribute
to persistent disparities in women’s health outcomes [5,6].
BV has a significant impact on the work productivity and quality-of-life of affected women, with 60% of
recurrent sufferers reporting a negative impact on work attendance, job performance and productivity,
and 95% reporting a severe restriction in intimate partner relations [7,8].
The current recommended regimen of a first-generation nitroimidazole requires twice-a-day dosing for
seven days for a total administration of seven grams of drug. Adherence with the current leading
therapy for the treatment of BV has been shown to be only approximately 50 percent . Poor
adherence to anti-infective therapy is a problem that increases with the length and complexity of the
drug regimen, and can lead to treatment failures, recurrent disease and the more rapid development of
resistant microorganisms . These, in turn, may lead to higher health care costs, including increased
out-of-pocket expenses, increased office visits and tests, additional treatment costs, and lost
About Symbiomix Therapeutics, LLC
Symbiomix (sim-bye-OH-mix) is a biopharmaceutical company bringing innovative medicines to market
for prevalent gynecological infections that can have serious health consequences. The Company’s lead
investigational drug Solosec™ (secnidazole) oral granules, a potent, next-generation 5-nitroimidazole
antibiotic, is anticipated to be the first and only single-dose oral treatment approved for bacterial
vaginosis (BV). Symbiomix was founded in 2012 by a team of experienced industry professionals and
entrepreneurs and is backed by three of the world’s leading healthcare venture capital firms: OrbiMed,
F-Prime Capital Partners, and HBM Partners. Symbiomix is based in New Jersey, with additional offices in
Maryland and Connecticut. Please visit www.symbiomix.com and follow the Company on LinkedIn and
Twitter for more information.
1. Allsworth J.E., Peipert, J.F. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstetrics and gynecology 2007; 109:114-20.
3. IMS Health, 2014
4. Bradshaw CS, et al. (2006). “High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence” J Infect Dis. 2006 Jun 1;193(11):1478-86.
6. Fiscella, K. (1996). “Racial disparities in preterm births. The role of urogenital infections.” Public Health Rep 111(2): 104-113.
7. Payne et al. (2010). “Evidence of African-American women’s frustrations with chronic, recurrent bacterial vaginosis.” Jn AANP 22(2010) 101-108.
8. Bilardi et al. (2013). “The Burden of Bacterial Vaginosis: Women’s Experience of the Physical, Emotional, Sexual and Social Impact of Living with Recurrent Bacterial Vaginosis.” PlusOne Sept 2013, vol 8, issue 9.
9. Bartley, J.B., et al. (2004). “Personal digital assistants used to document compliance of bacterial vaginosis treatment.” Sex Transm Dis 31(8): 488-491.
10. Kardas, P. (2002). “Once-Daily Dosage Secures Better Compliance With Antibiotic Therapy of Respiratory Tract Infections Than Twice-Daily Dosage.” WONCA Europe 2002 Conference, London.
11. Kardas, P., Bishai, W., (2006). “Compliance in anti-infective medicine.” Adv Stud Med 2006; 6(7C):S652:S658.
comments powered by